Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Harboring a BRAF V600 Mutation 1Ovarian Neoplasms 1Neoplasms by Site 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2 Negative Breast Cancer Not Immediately Operated 1Glioma 1Fallopian Tube Neoplasms 1ER+ HER2- Advanced Breast Cancer 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × ribociclib × Clear all
NCT01777776 2016-09-13

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Array BioPharma

Phase 1/2 Terminated
28 enrolled 14 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡